Evidence map›Paper›PMID 23147521›Full record

GuidelineThe American journal of gastroenterology2013

Clinical guideline: management of gastroparesis.

Michael Camilleri, Henry P Parkman, Mehnaz A Shafi, Thomas L Abell, Lauren Gerson, American College of Gastroenterology

7 registry-linked trialsAbstract readPractice Guideline
In one paragraph

Guideline in The American journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 425 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
425citing papers in PubMed, 16 pooled it
30.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03282084 withdrawnnot on this mapstarted 2017, after this paper: background citation

A Prospective, Observational Study of the PPI Non-responder

TypeobservationalSponsorDartmouth-Hitchcock Medical CenterRan2017 to 2018Enrolled0ConditionsGastro Esophageal Reflux Disease PPI Non-RespondersArmsEGD with biopsy, EGD and impedance-pH study on PPI
NCT04024709 completednot on this mapstarted 2017, after this paper: background citation

Long-term Results of Per-oral Pyloromyotomy for Refractory Gastroparesis

TypeobservationalSponsorUniversity Hospital, LimogesRan2017 to 2019Enrolled129ConditionsGastroparesisArmsGastric Peroral Endoscopic Myotomy
NCT04844190 nawithdrawnnot on this mapstarted 2021, after this paper: background citation

Use of Endoscopic Functional Lumen Imaging Probe (EndoFLIP) and Antroduodenal Manometry (ADM) in Predicting Clinical Response to Gastric Peroral Endoscopic Myotomy (G-POEM): A Pilot Study

TypeinterventionalSponsorNorthwestern UniversityRan2021 to 2024Enrolled0ConditionsGastroparesisArmsEndoFLIP, Antroduodenal Manometry
NCT05004012 nacompletednot on this mapstarted 2021, after this paper: background citation

AnX/Ankon Navicam Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility

TypeinterventionalSponsorUniversity of California, Los AngelesRan2021 to 2023Enrolled20ConditionsGastroparesis, DyspepsiaArmsMagnetically Controlled Capsule Endoscopy
NCT05789511 unknown statusnot on this mapstarted 2022, after this paper: background citation

High Resolution Electrogastrography (HR-EGG) Assessment in Medically Refractory Gastroparesis

TypeobservationalSponsorUniversity of VirginiaRan2022 to 2025Enrolled40ConditionsGastroparesis, Lung Transplant, ComplicationsArmsHigh Resolution Electrogastography
NCT05846802 recruitingnot on this mapstarted 2024, after this paper: background citation

Gastroparesis Registry 4 (GpR4): Improving the Understanding of Gastroparesis and Functional Dyspepsia

TypeobservationalSponsorJohns Hopkins Bloomberg School of Public HealthRan2024 to 2027Enrolled250ConditionsGastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus Type I, Gastroparesis Due to Diabetes Mellitus Type II
NCT05981300 recruitingnot on this mapstarted 2024, after this paper: background citation

GpCRC Pediatric Gastroparesis Registry 2: Characterization and Clinical Course of Symptoms and Gastric Emptying in Pediatric, Adolescent, and Young Adult Participants With Symptoms of Gastroparesis

Typeobservational_patient_registrySponsorJohns Hopkins Bloomberg School of Public HealthRan2024 to 2027Enrolled216ConditionsGastroparesis, Gastroparesis-like Syndrome
3 · Its place in the literature

Who cites it

425 citing papers in PubMed, 16 syntheses or guidelines pooled it, 1,127 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Guideline
  15. Guideline
  16. European guideline on indications, performance and clinical impact ofUnited European gastroenterology journal · 2021
    Guideline
  17. Trial
  18. Trial
  19. Trial
  20. Trial

365 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Michael CamilleriDepartment of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA. camilleri.michael@mayo.edu
Henry P Parkman
Mehnaz A Shafi
Thomas L Abell
Lauren Gerson
American College of Gastroenterology
Stanford University · USTemple University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Mississippi · USWinnMed · US

Funding

Physiological Characterization and Data Integration CoreP01DK068055 · NIDDK · MAYO CLINIC ROCHESTER · PI ORDOG, TAMAS · 2004 to 2019
$23.8M
Temple University Gastroparesis Clinical CenterU01DK073975 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI HENRY PAUL PARKMAN · 2006 to 2026
$7.4M
U of L Clinical Center to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis ConsortiumU01DK074007 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI Thomas Lyman Abell · 2006 to 2026
$7.0M
Pharmacogenomics of Gastric Function &Weight in ObesityR01DK067071 · NIDDK · MAYO CLINIC ROCHESTER · PI CAMILLERI, MICHAEL L. · 2004 to 2020
$4.7M
Pharmacogenomics of Gastric Function & Weight in ObesityR56DK067071 · NIDDK · MAYO CLINIC ROCHESTER · PI CAMILLERI, MICHAEL L. · 2015 to 2015
$396k
NIDDK NIH HHS 1 U01 DK073975-06NIDDK NIH HHS DK67071NIDDK NIH HHS P01 DK068055NIDDK NIH HHS P01 DK68055-04NIDDK NIH HHS R01 DK067071NIDDK NIH HHS R56 DK067071NIDDK NIH HHS U01 DK073975NIDDK NIH HHS U01 DK074007
6 · The paper itself

Abstract

This guideline presents recommendations for the evaluation and management of patients with gastroparesis. Gastroparesis is identified in clinical practice through the recognition of the clinical symptoms and documentation of delayed gastric emptying. Symptoms from gastroparesis include nausea, vomiting, early satiety, postprandial fullness, bloating, and upper abdominal pain. Management of gastroparesis should include assessment and correction of nutritional state, relief of symptoms, improvement of gastric emptying and, in diabetics, glycemic control. Patient nutritional state should be managed by oral dietary modifications. If oral intake is not adequate, then enteral nutrition via jejunostomy tube needs to be considered. Parenteral nutrition is rarely required when hydration and nutritional state cannot be maintained. Medical treatment entails use of prokinetic and antiemetic therapies. Current approved treatment options, including metoclopramide and gastric electrical stimulation (GES, approved on a humanitarian device exemption), do not adequately address clinical need. Antiemetics have not been specifically tested in gastroparesis, but they may relieve nausea and vomiting. Other medications aimed at symptom relief include unapproved medications or off-label indications, and include domperidone, erythromycin (primarily over a short term), and centrally acting antidepressants used as symptom modulators. GES may relieve symptoms, including weekly vomiting frequency, and the need for nutritional supplementation, based on open-label studies. Second-line approaches include venting gastrostomy or feeding jejunostomy; intrapyloric botulinum toxin injection was not effective in randomized controlled trials. Most of these treatments are based on open-label treatment trials and small numbers. Partial gastrectomy and pyloroplasty should be used rarely, only in carefully selected patients. Attention should be given to the development of new effective therapies for symptomatic control.

Indexed as

Acupuncture TherapyAntiemeticsBotulinum ToxinsCombined Modality TherapyDiabetes ComplicationsDiagnosis, DifferentialDiet TherapyElectric Stimulation TherapyFluid TherapyGastrectomyGastric BypassGastrointestinal AgentsGastroparesisGastrostomyHumansNeuromuscular AgentsAntiemeticsBotulinum ToxinsGastrointestinal AgentsNeuromuscular Agents

Identifiers

PMID23147521
PMCPMC3722580
OpenAlexW2122114281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.